Immuno Nutrition by L-citrulline for Critically Ill Patients (Immunocitre)
Primary Purpose
Intubation, Pulmonary Ventilation
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Enteral nutrition
L-Citrulline
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Intubation
Eligibility Criteria
Inclusion Criteria:
- age > 18 years
- medical patient (absence of recent surgery or trauma)
- initial aggression < 5 days
- mechanically ventilated with expected duration of mechanical ventilation > 2 days
- exclusive enteral nutrition
- absence of previous immunosuppression
Exclusion Criteria:
- severe sepsis
- septic shock
- obesity defined as BMI above 40
- pregnancy
Sites / Locations
- CHU Angers
- CHU Nantes
- Paris - HEGP
- Rennes Hospital University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
L-Citrulline group
Control group
Arm Description
Enteral nutrition 5-day L-citrulline treatment (10 grams/day)
Enteral nutrition 5-day placebo treatment
Outcomes
Primary Outcome Measures
Organ failure score comparison D7
Organ failure score (SOFA score) on day 7 in the L-citrulline group as compared to the placebo group
Secondary Outcome Measures
Organ failure score comparison D3
Organ failure score (SOFA score) on day 3 in the L-citrulline group as compared to the placebo group
SOFA score evolution between randomisation and D7
Binary criterion of success or failure :
- Success is defined by: an improved SOFA score of at least 2 points from randomization to Day 7 or an improvement in the general condition yielding the release of the unit;
- Failure is defined by an improved SOFA score but less than 2 points, no improvement or worsening of the SOFA score from randomization to Day 7 or the patient's death before J7;
Expression of HLA-DR
Expression of HLA-DR in the L-citrulline group as compared to the placebo group
Plasmatic concentration of IL6
Comparison of the plasmatic concentration of interleukin-6 between the L-citrulline group and the placebo group
HLA-DR
Comparison of the percentage of expression of monocytic HLA-DR between the L-citrulline group and the placebo group
Plasmatic concentration of L-arginine
Comparison of the plasmatic concentration of L-arginine and its metabolites between the L-citrulline group and the placebo group
Incidence of nosocomial infections
Comparison between the L-citrulline group and the placebo group
Length of stay
Length of stay in ICU and hospital: Comparison between the L-citrulline group and the placebo group
Mortality
Mortality in intensive care and in hospital : Comparison between the L-citrulline group and the placebo group
Duration of mechanical ventilation.
Duration of mechanical ventilation
Duration of mechanical ventilation: Comparison between the L-citrulline group and the placebo group
Full Information
NCT ID
NCT02864017
First Posted
August 4, 2016
Last Updated
June 8, 2020
Sponsor
Rennes University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02864017
Brief Title
Immuno Nutrition by L-citrulline for Critically Ill Patients
Acronym
Immunocitre
Official Title
Immuno Nutrition by L-citrulline for Critically Ill Patients
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
September 2016 (Actual)
Primary Completion Date
April 2019 (Actual)
Study Completion Date
April 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rennes University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main objective of this study is to demonstrate that the only administration of L-citrulline, can improve immune functions in critically ill patients at high risk of nosocomial infection.
Detailed Description
This is a multicentric therapeutic trial, randomized and double blind: standard enteral nutrition plus L-citrulline (5 grams/12 Hours for 5 days from the admission in Intensive Care Unit (ICU)) versus standard enteral nutrition plus placebo.
Methods-Patients: Non-surgical patients admitted in medical intensive care unit, under mechanical ventilation for an expected duration > 2 days, without severe sepsis or septic shock, will be enrolled. Symptoms leading for ICU admission ongoing for five days maximum. On admission (before treatment), the severity will be evaluated with the Sepsis-related Organ Failure Assessment (SOFA) score together with an assessment of plasmatic arginine, cytokines (InterLeukin-6 (IL6) ), and expression of Human Leukocyte Antigen - antigen D Related (HLA-DR) by monocytes. The same evaluation will be repeated on day 3 (during treatment) and on day 7 (after treatment).
The enrolment of 100 patients is statistically enough to demonstrate a decreased SOFA scores in the L-citrulline group as compared to the placebo group on day 7.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intubation, Pulmonary Ventilation
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
L-Citrulline group
Arm Type
Experimental
Arm Description
Enteral nutrition 5-day L-citrulline treatment (10 grams/day)
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Enteral nutrition 5-day placebo treatment
Intervention Type
Procedure
Intervention Name(s)
Enteral nutrition
Intervention Type
Dietary Supplement
Intervention Name(s)
L-Citrulline
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Organ failure score comparison D7
Description
Organ failure score (SOFA score) on day 7 in the L-citrulline group as compared to the placebo group
Time Frame
At day 7
Secondary Outcome Measure Information:
Title
Organ failure score comparison D3
Description
Organ failure score (SOFA score) on day 3 in the L-citrulline group as compared to the placebo group
Time Frame
At day 3
Title
SOFA score evolution between randomisation and D7
Description
Binary criterion of success or failure :
- Success is defined by: an improved SOFA score of at least 2 points from randomization to Day 7 or an improvement in the general condition yielding the release of the unit;
- Failure is defined by an improved SOFA score but less than 2 points, no improvement or worsening of the SOFA score from randomization to Day 7 or the patient's death before J7;
Time Frame
up to 7 days
Title
Expression of HLA-DR
Description
Expression of HLA-DR in the L-citrulline group as compared to the placebo group
Time Frame
At day 7
Title
Plasmatic concentration of IL6
Description
Comparison of the plasmatic concentration of interleukin-6 between the L-citrulline group and the placebo group
Time Frame
At day 7
Title
HLA-DR
Description
Comparison of the percentage of expression of monocytic HLA-DR between the L-citrulline group and the placebo group
Time Frame
At day 7
Title
Plasmatic concentration of L-arginine
Description
Comparison of the plasmatic concentration of L-arginine and its metabolites between the L-citrulline group and the placebo group
Time Frame
At day 7
Title
Incidence of nosocomial infections
Description
Comparison between the L-citrulline group and the placebo group
Time Frame
during the stay in the ICU, an average of 7 days
Title
Length of stay
Description
Length of stay in ICU and hospital: Comparison between the L-citrulline group and the placebo group
Time Frame
during the stay in hospital, up to 28 days
Title
Mortality
Description
Mortality in intensive care and in hospital : Comparison between the L-citrulline group and the placebo group
Duration of mechanical ventilation.
Time Frame
during the stay in hospital, up to 28 days
Title
Duration of mechanical ventilation
Description
Duration of mechanical ventilation: Comparison between the L-citrulline group and the placebo group
Time Frame
during the stay in ICU, an average of 7 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age > 18 years
medical patient (absence of recent surgery or trauma)
initial aggression < 5 days
mechanically ventilated with expected duration of mechanical ventilation > 2 days
exclusive enteral nutrition
absence of previous immunosuppression
Exclusion Criteria:
severe sepsis
septic shock
obesity defined as BMI above 40
pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Marc TADIE, MD
Organizational Affiliation
CHU Rennes
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Angers
City
Angers
Country
France
Facility Name
CHU Nantes
City
Nantes
Country
France
Facility Name
Paris - HEGP
City
Paris
Country
France
Facility Name
Rennes Hospital University
City
Rennes
ZIP/Postal Code
35033
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Immuno Nutrition by L-citrulline for Critically Ill Patients
We'll reach out to this number within 24 hrs